Holen Sie sich die Stockscreener-App
169.38
1.09%
1.83
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics, Inc. $AXSM Shares Sold by Peregrine Capital Management LLC - MarketBeat
Discipline and Rules-Based Execution in AXSM Response - Stock Traders Daily
Why Axsome Therapeutics Inc. stock is rated strong buyMarket Sentiment Indicators & Maximize ROI With Proven Growth Stocks - bollywoodhelpline.com
Why Axsome Therapeutics Inc. stock could outperform in 20252025 Market Overview & Verified Chart Pattern Signals - ulpravda.ru
Will Axsome Therapeutics Inc. stock reach all time highs in 2025July 2025 Drop Watch & Daily Price Action Insights - ulpravda.ru
How interest rate cuts could boost Axsome Therapeutics Inc. stock2025 Pullback Review & Weekly Top Performers Watchlists - ulpravda.ru
Can Axsome Therapeutics Inc. (19X) stock hold up in economic slowdown2025 Historical Comparison & Expert Approved Momentum Ideas - ulpravda.ru
How Axsome Therapeutics Inc. stock reacts to Fed rate cutsBreakout Watch & Fast Gain Swing Alerts - ulpravda.ru
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - MarketBeat
Morgan Stanley Downgrades Axsome Therapeutics to Equal Weight From Overweight, Adjusts PT to $204 From $196 - MarketScreener
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Morgan Stanley downgrades Axsome stock after 23% rally, raises price target - Investing.com Canada
Axsome therapeutics CEO sells $23.8m in shares By Investing.com - Investing.com UK
Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) CEO Sells 29,450 Shares of Stock - MarketBeat
Herriot Tabuteau Sells 31,261 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Equities Analysts Set Expectations for AXSM Q2 Earnings - MarketBeat
UBS Adjusts Price Target on Axsome Therapeutics to $248 From $163, Maintains Buy Rating - MarketScreener
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
H.C. Wainwright raises Axsome Therapeutics stock price target on FDA priority review - Investing.com Canada
Axsome Therapeutics (AXSM) Stock Analysis: Revenue Growth Soars Amid Biotech Innovations - DirectorsTalk Interviews
AXSM: HC Wainwright & Co. Raises Price Target to $200 and Mainta - GuruFocus
Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics - The Pharma Letter
Axsome Therapeutics Insider Sold Shares Worth $6,206,969, According to a Recent SEC Filing - MarketScreener
Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next - Yahoo Finance
Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 - Yahoo Finance
Axsome therapeutics director Saad sells $6.2m in shares By Investing.com - Investing.com Canada
Mark Saad Sells 37,577 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Glaukos (GKOS) - The Globe and Mail
A Comprehensive Guide To Axsome: Unlocking The Potential Of Innovative Therapeutics- - shababeek.org
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation - Finviz
Truist Securities reiterates Buy rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? - Yahoo Finance
Deutsche Bank Raises Price Target on Axsome Therapeutics to $223 From $186, Keeps Buy Rating - MarketScreener
FDA grants Axsome’s AXS-05 sNDA priority review designation - The Pharma Letter
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation - ts2.tech
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug - ts2.tech
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - The Globe and Mail
Axsome (AXSM) Stock; Climbs Nearly 23% After FDA Accelerates Alzheimer’s Review - CoinCentral
Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - MSN
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Nigeria
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - AOL.com
Key Takeaways - StocksToTrade
Axsome’s Surprising Surge: What’s Next ? - timothysykes.com
From Haiti to Wall Street to Big Pharma: Herriot Tabuteau is on a $6B mission to heal the brain - AOL.com
Axsome Therapeutics price target raised to $217 from $202 at Mizuho - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Nigeria
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - ts2.tech
Axsome Therapeutics says AXS-12 NDA submission on track for January - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock - Investing.com
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):